Recruiting

Praziquantel & Albendazole

Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Code:

NCT00001205

Conditions

Cysticercosis

Neurocysticercosis

Eligibility Criteria

Sex: All

Age: 3 - 70+

Healthy Volunteers: Accepted

Study Details

Brief summary:

Neurocysticercosis is a brain disease due to the larval stage of the pork tapeworm (Taenia solium). The most common symptoms patient experience from infection inside the substance of the brain (parenchymal disease) are seizures and headaches. When the infection is either inside the fluid pockets inside the brain (ventricular disease) or in the space around the brain (subarachnoid disease) patients can have chronic headaches, relapsing aseptic meningitis, hydrocephalus, stroke, and may require neurosurgical intervention. The purpose of this study is to treat patients with anthelmintic therapy (praziquantel and/or albendazole) and anti-inflammatories in alignment with currently accepted best practices and guidelines, depending on the neurocysticercosis subtype. The purpose of the study is to better understand and characterize clinical, biologic, and management factors during treatment that influence long term outcomes. In order to understand this further we collect patient clinical information, patient survey responses, blood, urine samples, and additional cerebral spinal fluid if already being collected for clinical care.

Conditions

Cysticercosis

Neurocysticercosis

Study ID

NCT00001205

Start date

Oct 7, 1985

Status verified date

Aug 26, 2026

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 3 - 70+

Healthy Volunteers: Accepted

  • INCLUSION CRITERIA:

Arms 1-5 (NCC):

1. Aged 3 years and older.
2. Ability of participant (or legally authorized representative, LAR) to understand and the willingness to sign a written informed consent document.
3. Patients with proven or likely NCC

Arm 6 (Endemic Exposures):

1. Patient with epidemiologic history compatible with possible exposure to NCC
2. Aged 18 years and older.

EXCLUSION CRITERIA:

Not applicable

Study Design

Enrollment

500 participants

Anticipated

Interventions and Outcome Measures

Arms

Arm 1

Subarachnoid (racemose) neurocysticercosis

Arm 2

Ventricular without other viable disease

Arm 3

Parenchymal cyst(s)--non-calcified parenchymal disease at time of referral

Arm 4

Calcified parenchymal disease with symptoms (seizures)

Arm 5

Calcified parenchymal disease without symptoms

Arm 6

Endemic exposure--subjects with compatible epidemiologic exposure to T. solium

Primary outcome measure

  • The primary objective is to characterize the biochemical and clinical course of neurocysticercosis (NCC) during and after treatment with long-term follow-up. [ Time Frame: Ongoing ]

Central Contacts and Locations

Central contacts

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

More Information

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Last update posted

Sep 8, 2026

Last verified

Aug 26, 2026

Keywords

  • Tapeworm
  • Taenia Solium
  • Neurocysticercosis
  • Natural History
  • Seizures
  • Aseptic Meningitis
  • Hydrocephalus

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Institute of Allergy and Infectious Diseases (NIAID) on 2026-09-08.